Steven P Treon MD

Oncology•Boston, MA

Associate Professor of Medicine, Dana-Farber Cancer Institute

Join to View Full Profile

44 Binney StBoston, MA 02115
Phone+1 617-632-4166
Fax+1 617-632-4862

Summary

Dr. Steven Treon is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, and North Shore Medical Center. He received his medical degree from Boston University School of Medicine and has been in practice 24 years. He specializes in hematologic oncology and is experienced in hematologic oncology and waldenstrom macroglobulinemia.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1995 - 1997
Boston University Medical CenterResidency, Internal Medicine, 1992 - 1995
Boston University School of MedicineClass of 1993

Certifications & Licensure

MA State Medical License 1994 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Start of enrollment: 2003 May 01
Completed
Phase 2
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia Start of enrollment: 2003 Dec 01
Completed
Phase 2
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia Start of enrollment: 2002 Jan 01
Completed
Not Applicable
CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia Start of enrollment: 2004 Sep 01
Terminated
Phase 2
Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia Start of enrollment: 2003 Mar 01
Completed
Phase 2
Sildenafil Citrate in Waldenstrom's Macroglobulinemia Start of enrollment: 2005 Sep 01
Completed
Phase 2
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Start of enrollment: 2005 Oct 01
Completed
Phase 2
Simvastatin in Waldenstrom's Macroglobulinemia Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Start of enrollment: 2009 Nov 01
Completed
Phase 2
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia Start of enrollment: 2010 May 01
Terminated
Phase 1
Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Start of enrollment: 2011 Oct 01
Completed
Phase 2
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Start of enrollment: 2012 May 01
Completed
Phase 2
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing Start of enrollment: 2016 Jan 01
Completed
Phase 2
ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies Start of enrollment: 2020 Feb 03
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia.
Jonas Paludo, Jithma P Abeykoon, Nirosha D Perera, Shayna Sarosiek, Joshua Gustine
American Journal of Hematology. 2025-03-10
Zanubrutinib for the treatment of Bing-Neel syndrome.
Shayna Sarosiek, Andres Ramirez-Gamero, Catherine A Flynn, Steven P Treon, Jorge J Castillo
British Journal of Haematology. 2025-02-18
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's Macroglobulinemia.
Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, Ting Wu, Nicholas Tsakmaklis
Nature Communications. 2025-02-10

Journal Articles

Bortezomib Overcomes the Negative Impact of CXCR4 Mutations on Survival of Waldenstrom's Macroglobulinemia Patients
Kaitlen Reyes, Steven P Treon, Irene M Ghobrial, Blood
TP53 Mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinaemia
Toni Dubeau, Steven P Treon, Jorge J Castillo, Christopher J Patterson, British Journal of Haematology
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
Jeffrey V Matous, M Lia Palomba, Steven P Treon, The New England Journal of Medicine

Abstracts/Posters

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 M...
Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High-Dimensional Heterogeneity of Waldenstr_m Macroglobulinemia within Its Immune Tumor Microenvironment
Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenstr_m Macroglobulinemia Treated with Ibrutinib
Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells
Steven P Treon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CXCR4 Mutational Status Does Not Impact Outcomes in Patients with Waldenstrom Macroglobulinemia Treated with Proteasome Inhibitors
Steven P Treon, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Join now to see all

Lectures

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Dose Reduction Does Not Affect Progression-Free Survival in Patients with Waldenstrom Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MY...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib for the Treatment of Bing-Neel Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom’s Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTKCys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

FDA Greenlights BeiGene’s Brukinsa for Waldenstrom’s MacroglobulinemiaSeptember 2nd, 2021
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström’s MacroglobulinemiaSeptember 1st, 2021
BTK Blockers Make Headway in Multiple SclerosisJanuary 11th, 2021
Join now to see all